Rachel Delston

Rachel Delston, Ph.D., is an experienced professional in drug discovery and development, currently serving as a Consultant at Mirada Life Sciences since January 2023. Prior roles include Associate Director at Arch Oncology from April 2019 to July 2022, Director of Research and Development at Canopy Biosciences from January 2017 to April 2019, and Principal Scientist at Confluence Discovery Technologies and Confluence Life Sciences from May 2013 to January 2017. Rachel's academic background includes a Ph.D. in Molecular and Cellular Biology from Washington University in St. Louis, where research focused on functionalizing whole genome sequencing of estrogen receptor positive breast cancer, alongside earlier research roles at prestigious institutions such as the University of California, San Francisco, and the National Cancer Institute.